Fate Therapeutics Inc (FATE)
3.80
-0.07
(-1.81%)
USD |
NASDAQ |
Apr 26, 16:00
3.795
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Cash from Financing (Quarterly): -0.18M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.18M |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.058M |
| March 31, 2023 | 0.207M |
| December 31, 2022 | 1.517M |
| September 30, 2022 | 1.487M |
| June 30, 2022 | 3.406M |
| March 31, 2022 | 2.797M |
| December 31, 2021 | 3.418M |
| September 30, 2021 | 7.942M |
| June 30, 2021 | 3.719M |
| March 31, 2021 | 438.05M |
| December 31, 2020 | 4.91M |
| September 30, 2020 | 0.93M |
| June 30, 2020 | 275.55M |
| March 31, 2020 | 1.451M |
| December 31, 2019 | -13.72M |
| September 30, 2019 | 161.70M |
| June 30, 2019 | 0.688M |
| March 31, 2019 | 1.258M |
| December 31, 2018 | 1.904M |
| September 30, 2018 | 137.36M |
| Date | Value |
|---|---|
| June 30, 2018 | 1.156M |
| March 31, 2018 | 0.355M |
| December 31, 2017 | 43.24M |
| September 30, 2017 | 8.299M |
| June 30, 2017 | -2.012M |
| March 31, 2017 | -2.17M |
| December 31, 2016 | 53.08M |
| September 30, 2016 | 8.287M |
| June 30, 2016 | -1.907M |
| March 31, 2016 | -1.726M |
| December 31, 2015 | -0.90M |
| September 30, 2015 | -0.533M |
| June 30, 2015 | 36.96M |
| March 31, 2015 | 0.075M |
| December 31, 2014 | 9.996M |
| September 30, 2014 | 9.226M |
| June 30, 2014 | -0.354M |
| March 31, 2014 | -0.502M |
| December 31, 2013 | 39.68M |
| September 30, 2013 | 19.17M |
| June 30, 2013 | 2.206M |
| March 31, 2013 | -0.50M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-13.72M
Minimum
Dec 2019
438.05M
Maximum
Mar 2021
47.05M
Average
1.517M
Median
Dec 2022
Cash from Financing (Quarterly) Benchmarks
| Amicus Therapeutics Inc | 8.21M |
| Regeneron Pharmaceuticals Inc | -446.10M |
| Sarepta Therapeutics Inc | 1.943M |
| ADMA Biologics Inc | -38.99M |
| Ocular Therapeutix Inc | 108.17M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -36.64M |
| Cash from Investing (Quarterly) | 45.35M |
| Free Cash Flow | -138.42M |
| Free Cash Flow Per Share (Quarterly) | -0.3733 |
| Free Cash Flow to Equity (Quarterly) | -36.82M |
| Free Cash Flow Yield | -37.01% |